– Sponsor of the Heart of Genetic Counseling program and award, recognizing excellence in patient care –
– These studies combined with new digital tools aim to increase access and frequency of hereditary cancer screening both before and during treatment –
SAN FRANCISCO, Oct. 10, 2023 /PRNewswire/ — Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are showcasing their work next week at the National Society of Genetic Counselors (NSGC) 42nd Annual Conference in Chicago that highlights the importance of genetics-informed patient care. In addition to its research presentations, the company will present the Heart of Genetic Counseling Award which recognizes excellence in the field of genetic counseling.
The company’s research presentations, which include a sponsored session, oral presentations and posters, present data on improvements in classifying Variants of Uncertain Significance (VUS), how using digital tools can increase hereditary cancer screening access and other topics related to the field of medical genomics. The sponsored session will focus on the ever-evolving field of genetic counseling and the tools needed to navigate change through an interactive workshop using the odyssey planning framework.
“The NSGC Annual Conference is a great opportunity for Invitae researchers to share cutting-edge scientific advancements with genetic counselors who play an integral role in genetics-informed patient care,” said Robert Nussbaum, M.D., chief medical officer at Invitae. “It also gives us a chance to show our continued commitment to genetic counselors and their patients by awarding the Heart of Genetic Counseling Award to a genetic counselor who was nominated by a patient for extraordinary care and compassion.”
Heart of Genetic Counseling Award
Invitae joins NSGC in presenting the Heart of Genetic Counseling Award – honoring excellence in genetic counseling and patient care as recognized by patients. The nominations include patient stories that highlight the significant clinical and personal impact their genetic counselor had on their lives and the lives of their families. This year’s award will be presented during the ceremony on Wednesday, October 18, at 7 p.m. CT. Among several nominations, the finalists are:
Leslie Walsh Cyprych MS, MPH, CGC, Children’s Hospital of Pittsburgh, was nominated by a mother for providing unwavering patient advocacy, support and compassion after her daughter was diagnosed with Aicardi-Goutieres syndrome (AGS), a rare, progressive, and incurable genetic disease. Cyprych has continuously gone above and beyond to coordinate the daughter’s care, help navigate the healthcare system, and to provide information and meaningful emotional support.
Andrea Gainey MS, LCGC, UConn Health Huntington’s Disease Program, provided crucial care, comfort and guidance to a family facing Huntington’s Disease (HD). Gainey understands the stigma that surrounds HD and how difficult the decision to test is and helped establish free anonymous testing and confidential lab reports. Considered a leader in the HD community, Gainey has helped generations of families deal with this devastating disease on a daily basis.
Victoria Suslovitch MS, CGC, Ambry Genetics, formerly with Boston Children’s Hospital, was nominated for offering compassion, emotional support and guidance to a family whose son is affected by a devastating rare genetic disease, called KCNQ2 developmental epileptic encephalopathy. Suslovitch was a guiding light helping each family member deal with their frightening medical journey. Suslovitch drew on her personal experience to connect with siblings as both a peer and professional and taught healthy coping mechanisms.
The Heart of Genetic Counseling Award will be presented on Wednesday, October 18, from 7 p.m. to 9 p.m. CT.
Full presentation schedule
Invitae continues to demonstrate scientific innovation and excellence as supported by the number of accepted sessions, presentations, and posters. The full schedule of Invitae presentations and posters at the conference can be found on our website.
Wednesday, October 18
- Poster CAN65. Cascade testing with comprehensive multigene panels for hereditary cancer identifies unexpected findings in relatives. | Presented by: Brandie Heald, M.S., C.G.C., Invitae. | 5:30 p.m. – 7 p.m. CT
- Poster CAN75. One of these is not like the others: a descriptive study of the attenuated phenotype of PMS2 | Presented by: Brandie Heald, M.S., C.G.C., Invitae. | 5:30 p.m – 7 p.m. CT
- Poster CAN67. Patient uptake of physician recommendations following prostate cancer germline genetic testing. | Presented by: Sarah M. Nielsen, Invitae. | 5:30 p.m. – 7 p.m. CT
- Heart of Genetic Counseling Award Presentation | Presented by: Invitae and NSGC. | 7 p.m. – 9 p.m. CT
Thursday, October 19
- Educational Breakout Session C03. Increasing access to hereditary cancer screening: emerging evidence on the use of digital tools for ascertainment of individuals at risk and considerations for care delivery. | Presented by: Shivani Nazareth, M.S., C.G.C., Wendy Kohlmann, M.S., C.G.C., Vera Cherepakho, L.C.G.C., Meredith Gerhart, M.S., C.G.C., Sarah Knerr, Ph.D., Catharine Wang, Ph.D., Rebecca Carr, M.S., C.G.C., Colleen Caleshu, M.S., C.G.C., Sarah Savage, M.S., C.G.C. | 11 a.m. – 12:30 p.m. CT
- Sponsored session. Charting your genetic counseling odyssey: Navigating with purpose and vision. | Presented by: Jennifer Young, Ph.D., Feinberg School of Medicine Northwestern University, and Ana Morales, M.S., C.G.C., Invitae. | 12:45 p.m. – 2 p.m. CT
- Poster CAN64. The estimated healthcare spend to identify one hereditary cancer syndrome patient with a deep intronic pathogenic variant by RNA sequencing is nearly 500x more costly than identifying one patient with multi-gene panel DNA testing. | Presented by: Brandie Heald, M.S., C.G.C., Invitae. | 4:30 p.m. – 6:30 p.m. CT
- Poster GGT218. Minimizing uncertainty and increasing equity in genetic testing: the role of machine learning tools in the classification of genetic variants. | Presented by: Flavia M. Facio, M.S., C.G.C.. Invitae. | 4:30 p.m. – 6:30 p.m. CT
- Poster GGT282: Utilization of an Automated, Probability-Based Algorithm to Determine Pharmacogenomic Adverse Drug Outcome Risk in Cancer Patients. | Presented by: Sienna Aguilar, M.S., L.C.G.C., Invitae. | 4:30-6:30 p.m.
- Poster GGT256. Positive yield of reproductive carrier screening in the context of revised ACMG recommendations for tiered carrier screening. | Presented by: Dana Neitzel, M.S., C.G.C., Invitae. | 4:30-6:30 p.m. CT
- Oral Presentation B16. User Testing of a Pre-Visit Chatbot Developed for Population Genomic Screening and Counseling. | Presented by: Kelly Morgan, M.S., C.G.C. | 4:45-5:45 p.m. CT
- Oral Presentation B17. Yield of integrated DNA and RNA analysis of hereditary cancer associated genes based on cancer diagnosis. | Presented by: Brandie Heald, M.S., C.G.C., Invitae. | 4:45 – 5:45 p.m. CT
Friday, October 20
- Oral Presentation C14. A Pilot Study Comparing the Effectiveness of Pre-test Genetic Counseling Using a Chatbot versus Traditional In-person Genetic Counseling in Women Newly Diagnosed with Breast Cancer. | Presented by: Ryan Noss, M.S., C.G.C. | 10:15 a.m. – 11:15 a.m. CT
On-demand session
- Advancing Variant Classification: Steps in Reducing Uncertainty and Improving Patient Outcomes. | Presented by: Heidi Rehm, Ph.D., Yuya Kobayashi, Ph.D., Jason Carmichael, M.S., C.G.C., Sayoni Lahiri, C.G.C., Flavia M. Facio C.G.C. | Available in the live stream and on-demand portions of the program via NSGC conference app.
To learn more about Invitae’s presence at the NSGC 42nd Annual Conference or the Heart of Genetic Counseling Award, visit our website.
About Invitae
Invitae (NYSE: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae’s genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.
To learn more, visit invitae.com and follow for updates on Twitter, Instagram, Facebook and LinkedIn @Invitae.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the content of the company’s research presentations and posters; the objectives of the company’s studies and tools; and the company’s beliefs regarding the quality and impact of its research. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s ability to grow its business in a cost-efficient manner; the company’s history of losses; the company’s ability to maintain important customer relationships; the company’s ability to compete; the company’s need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the applicability of clinical results to actual outcomes; the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; risks associated with litigation; security breaches, loss of data and other disruptions; laws and regulations applicable to the company’s business; and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.
Contact:
Amanda McQuery
[email protected]
(628) 213-3283
SOURCE Invitae Corporation
